An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36107417/
doi: 10.1001/jamaoncol.2022.4175. Online ahead of print. 1 Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. 2 Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. 3 Department of Medicine, University of Barcelona, Barcelona, Spain. 4 Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Conclusions and Relevance: This review suggests that ERBB2-low may be a distinct, clinically relevant breast cancer entity warranting reassessment of traditional diagnostic and therapeutic paradigms. Ongoing clinical trials and further investigations may provide optimized strategies for diagnosing and treating ERBB2-low breast cancer, including reproducible, consistent definitions to identify patients in this diagnostic category and demonstration of benefits of emerging therapies.